BioStock: PHI’s CEO comments on the approved US listing

August 21, 2024
Language flag

Phase Holographic Imaging has been approved for a dual US listing in addition to its primary listing on the Swedish Spotlight market. What does this mean for the company’s shareholders, and how might it impact the company’s long-term valuation? BioStock reached out to PHI’s CEO Patrik Eschricht to discuss this and the upcoming redemption of the TO4 warrants that could potentially raise SEK 20.8 million in October.

Read the full interview with Patrik Eschricht on biostock.se.

The dual listing on the OTCQB market represents a significant step in
making PHI’s shares more accessible to US investors. This listing
increases our visibility in the US, aligning with our strategic focus on
expanding into the regenerative medicine market.

Further reading

Swiss-based Altium major investor BioStock

BioStock: PHI catches eye of major investor

BioStock contacted Altium’s CEO Goran Dubravcic to learn more about their incentives to invest in PHI.
Patrik Eschricht and Peter Egelberg shaking hands

BioStock: PHI comments on the new senior positions in the company

BioStock reached out to Patrik Eschricht and Peter Egelberg to better understand the background behind the recent management shift.
PHI CSO Kersti Alm at Biostock

BioStock: PHI on the alliance for cell-based biomanufacturing

Kersti Alm, CSO at PHI, visited BioStock’s studio to talk about the recently created alliance for advancing cell-based biomanufacturing and PHI’s pivotal role in the collaboration.
PHI part of new regenerative medicine alliance

BioStock: PHI part of new regenerative medicine alliance

BioStock contacted Product Manager Lisa Lindström to learn more about PHI’s newly formed technology development alliance for regenerative medicine and what excites her about the future.
1…678910

Latest News

phi-right-moment-to-capitalize-on-regenerative-medicine-momentum

BioStock: PHI’s new CEO: “I am excited to lead us forward with new energy”

Anders Månsson was recently appointed CEO of Phase Holographic Imaging. With extensive leadership experience in the international life sciences sector, he aims to expand PHI’s global reach and position the company as a leader in non-invasive cell quality control technologies. BioStock spoke with him about his vision for the future.

Bulletin from the annual general meeting of Phase Holographic Imaging PHI AB (publ)

Phase Holographic Imaging PHI AB (publ) held its annual general meeting on 31 October 2024. The following resolutions were made.

PHI secures a loan from Altium SA

Phase Holographic Imaging PHI AB (“PHI”) announces that the Company has been provided a loan of SEK 7 million from the main shareholder Altium SA. PHI and Altium SA are also in dialogues regarding long-term financing of PHI.
See All News